lewis-y-antigen and Cystadenocarcinoma--Serous

The purpose of this study was to investigate the relationship between the expression of CD147 and Lewis y antigen in epithelial ovarian carcinoma tissues and resistance to chemotherapeutic drugs, and its underlying clinical significance, and to analyze the correlation between the expression of CD147 and Lewis y antigen. Ninety-two ovarian cancer patients were divided into a chemotherapeutic-drug-resistant group (34 patients) and a drug-sensitive group (58 patients). Immunohistochemical assays were used to measure CD147, and Lewis y antigen to investigate their correlation with chemotherapy resistance. Multivariate logistic regression was used to analyze the relationships between risk factors and resistance to chemotherapy in ovarian cancer. Cox's model was used to analyze the relationships between risk factors and prognosis. The proportion of tissues expressing CD147 and Lewis y antigen in the drug-resistant group were 94.12 and 91.67%, respectively, which were significantly higher than those in the sensitive group (77.59 and 60.34%, respectively). The multivariate analysis indicated that the expression of CD147 and Lewis y antigen and the pathological stage of the ovarian cancer were all independent risk factors for drug resistance. Expression of CD147 and Lewis y antigen was high in the resistant group, and they correlated positively with each other. The expression of CD147 and Lewis y antigen was significantly higher in the drug-resistant group and their expression correlated positively in the ovarian epithelium. The expression of CD147 and Lewis y antigen and the pathological stage of ovarian cancer were all independent risk factors for drug resistance and prognosis in ovarian cancer.

Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Basigin; Biomarkers, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lewis Blood Group Antigens; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Survival Rate

This study investigates the expression and the clinical significance of Lewis y and integrins α5 and β1 in serous and mucinous ovarian tumors and then evaluates the association between them.. Lewis y and integrin α5 and β1 expression are detected on tissues from malignant, borderline, and benign ovarian serous and mucinous tumors and normal tissues. Their expression and relationship are assessed in paraffin sections using immunohistochemistry and double-labeling immunofluorescence method.. Lewis y was mainly expressed in ovarian serous and mucinous cancers (88.33%); its positive rate was obviously higher than rates in the borderline (60.00%, P < 0.05) and benign ovarian tumors (35.00%, P < 0.01) and normal ovarian tissues (0, P < 0.01) and was not associated with clinicopathological characteristics. Integrins α5 (85.00%) and β1 (81.67%) were also mainly expressed in ovarian serous and mucinous cancers; their positive rates were all obviously higher than those in benign ovarian tumors (60.00% and 55.00%, respectively; all P < 0.05) and normal tissues (40.00% and 30.00%, respectively; all P < 0.01). Increased expression of integrins α5 and β1 correlated with higher clinical stage (P < 0.05) but were not associated with histological types, differentiation degree, and lymphatic metastasis (P > 0.05). The expression intensity of Lewis y and integrins α5 and β1 was significant with clinical stage and differentiation degree (all P < 0.05) in ovarian cancer; positive significant correlation between Lewis y antigen and integrins α5 and β1 was observed in serous and mucinous ovarian cancer tissues.. A close correlation between Lewis y, integrins α5 and β1, and ovarian cancer was observed. Lewis y can influence the biological behavior of a tumor cell as an important composition of integrins α5 and β1 by some signal pathway, such as promoting cell adhesion and migration, and this study provides theoretical evidence of ovarian cancer biological treatment.

Topics: Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Biomarkers, Tumor; Case-Control Studies; Cystadenocarcinoma, Serous; Female; Humans; Integrin alpha5; Integrin alpha5beta1; Integrin beta1; Lewis Blood Group Antigens; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Young Adult